Tyrosine kinase inhibitors (TKIs) against targetable mutations such as epidermal growth factor receptor (EGFR) are highly efficient in treating advanced stage lung cancers. The usage of EGFR inhibitors (EGFRI) is associated with an improved response rate and improved Progression-free survival (PFS) compared to chemotherapy. Frequently expressed EGFR mutants include 19del, T790M, L858R and recently discovered secondary mutation C797S. There is also some possibility to improve outcome by focusing on better EGFRI and/or combining EGFRI with other therapies like chemotherapy, vascular endothelial growth factor (VEGF) inhibitors and immunotherapy. This review provides an overview of the current status and potential future for EGFR therapies and LUNG CANCER treatments.